Language:

Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association

Circulation (New York, N.Y.), 2020-07, Vol.142 (1), p.e7-e22 [Peer Reviewed Journal]

2020 by the American College of Cardiology Foundation and the American Heart Association, Inc. ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIR.0000000000000792 ;PMID: 32476490

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association
Author: Kittleson, Michelle M ; Maurer, Mathew S ; Ambardekar, Amrut V ; Bullock-Palmer, Renee P ; Chang, Patricia P ; Eisen, Howard J ; Nair, Ajith P ; Nativi-Nicolau, Jose ; Ruberg, Frederick L
Subjects: Algorithms ; Alleles ; Amyloidosis - diagnosis ; Amyloidosis - etiology ; Amyloidosis - metabolism ; Amyloidosis - therapy ; Animals ; Biomarkers ; Cardiomyopathies - diagnosis ; Cardiomyopathies - etiology ; Cardiomyopathies - metabolism ; Cardiomyopathies - therapy ; Clinical Decision-Making ; Disease Management ; Disease Susceptibility ; Gene Silencing ; Genetic Predisposition to Disease ; Genotype ; Heart Function Tests ; Humans ; Magnetic Resonance Imaging ; Molecular Diagnostic Techniques ; Prealbumin - genetics ; Prealbumin - metabolism
Is Part Of: Circulation (New York, N.Y.), 2020-07, Vol.142 (1), p.e7-e22
Description: Transthyretin amyloid cardiomyopathy (ATTR-CM) results in a restrictive cardiomyopathy caused by extracellular deposition of transthyretin, normally involved in the transportation of the hormone thyroxine and retinol-binding protein, in the myocardium. Enthusiasm about ATTR-CM has grown as a result of 3 simultaneous areas of advancementImaging techniques allow accurate noninvasive diagnosis of ATTR-CM without the need for confirmatory endomyocardial biopsies; observational studies indicate that the diagnosis of ATTR-CM may be underrecognized in a significant proportion of patients with heart failure; and on the basis of elucidation of the mechanisms of amyloid formation, therapies are now approved for treatment of ATTR-CM. Because therapy for ATTR-CM may be most effective when administered before significant cardiac dysfunction, early identification of affected individuals with readily available noninvasive tests is essential. This scientific statement is intended to guide clinical practice and to facilitate management conformity by covering current diagnostic and treatment strategies, as well as unmet needs and areas of active investigation in ATTR-CM.
Publisher: United States: by the American College of Cardiology Foundation and the American Heart Association, Inc
Language: English
Identifier: ISSN: 0009-7322
EISSN: 1524-4539
DOI: 10.1161/CIR.0000000000000792
PMID: 32476490
Source: Geneva Foundation Free Medical Journals at publisher websites
MEDLINE

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association

2020 by the American College of Cardiology Foundation and the American Heart Association, Inc. ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIR.0000000000000792 ;PMID: 32476490

Searching Remote Databases, Please Wait